Chemed Corporation (CHE) Presents at 2026 Jefferies Healthcare Services and Technology Conference Transcript

Chemed said its second-quarter performance was slightly better than expected and raised full-year guidance. VITAS hospice trends remained solid, while Roto-Rooter is focused on stabilizing performance amid unfavorable marketing-cost comparisons as Google's changes reduced the share of free leads from nearly 60% to just under 40% over roughly two years. The outlook is constructive overall, but Roto-Rooter's paid-lead pressure remains a margin and growth headwind.

Analysis

CHE’s key valuation question is whether VITAS can compound earnings fast enough to offset a structurally lower-margin Roto-Rooter customer-acquisition model. The search-channel shift is not merely a one-quarter advertising headwind: converting organic calls into paid leads raises the recurring cost to acquire revenue and could depress Roto-Rooter incremental margins even if demand stabilizes. This makes consolidated guidance durability more dependent on hospice census, reimbursement discipline, and labor productivity over the next 6-18 months.

GOOG is the quiet beneficiary because local-services monetization transfers economics from fragmented service operators to the search platform. Larger branded operators such as Roto-Rooter may ultimately absorb this better than independent plumbing competitors, which lack scale marketing analytics and call-center conversion infrastructure; that could create share gains, but only after a margin-reset period. The market may be too quick to treat stable revenue as evidence of a recovered Roto-Rooter profit model—watch marketing expense as a percentage of revenue and lead conversion, not just revenue growth.

Near term, the raised outlook limits downside if execution remains intact, but the catalyst path is uneven: the next 1-3 months require evidence that paid-search inflation has plateaued, while the 6-18 month upside case requires VITAS growth to sustain consolidated EPS expansion despite lower service-business contribution. The thesis is falsified by a renewed reduction in Roto-Rooter margin expectations, a material slowdown in VITAS admissions/census growth, or evidence that paid leads are reducing customer lifetime value rather than simply changing acquisition mix.

Key Decisions for Investors

• Maintain a modest long CHE only on pullbacks rather than chase conference-driven strength; add if the next earnings release shows stable or improving Roto-Rooter marketing expense as a percentage of revenue alongside maintained full-year guidance. Risk/reward is favorable only if VITAS remains the dominant incremental earnings contributor.
• Use CHE as a quality-defensive healthcare-services holding over a 6-18 month horizon, but size below a pure-play hospice exposure because Roto-Rooter introduces consumer-demand and digital-acquisition-cost volatility.
• Avoid a directional GOOG trade on this item alone; instead, monitor local-search and advertising disclosures for confirmation that higher paid-lead penetration is broad-based across home services. Broad confirmation would be incrementally supportive of GOOG’s local-services monetization over subsequent quarters.
• Set a downside risk trigger for CHE at any guidance cut attributed to Roto-Rooter acquisition costs or weakening VITAS census trends; such a revision would challenge the assumption that the non-healthcare drag is temporary and could drive multiple compression.